Fig. 4.

Identifying the probable allelic involvement in relation to clinical and cytogenetic factors. A Frequency and importance of number of concurrent somatic mutations and cytogenetic abnormalities with Kaplan–Meier survival estimates comparing acute myeloid leukemia (AML) vs. myelodysplastic syndrome (MDS) for each group. Median variant allele frequency (VAF) for AML vs. MDS. B Kaplan–Meier survival estimates comparing obligatory biallelic, probable biallelic, and probable monoallelic mutations in double hits and single hit groups